Adalimumab Biosimilar in Clinical Practice
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Study ID
- NCT04808739
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - 90 Years
- Healthy Volunteers
- Accepted
Interventions
- Adalimumab — BIOLOGICALAnalysis of survival of adalimumab biosimilar in clinical practice
Study Details
This is an observational, retrospective, multicenter, and descriptive study of patients treated with adalimumab biosimilar for psoriasis, according to clinical practice. Existing data will be collected from the Dermatology Services database of the hospitals participating in the study, from the medical histories of all treated patients who meet the inclusion criteria and sign informed consent. The aim of the study is to determine the effectiveness of the different adalimumab biosimilars in clinical practice.
Key Dates
- Start date
- Jun 1, 2020
- Status verified
- Mar 2021
- Primary completion
- Feb 28, 2021
- Completion
- Feb 28, 2021
Study Design
- Enrollment
- 604 participants (actual)
Primary Outcome Measure
Median time of survival (months) of adalimumab biosimilar in clinical practice [ Time Frame: 1 year ]
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Regulation of Inflammatory Genes in PsoriasisRecruiting · University of Alabama at Birmingham · Birmingham, Alabama
- LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe PsoriasisEnrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
- An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis PatientsRecruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey